M Miletić1, T Vuk2, A Hećimović3, M Stojić Vidović4, L Jemeršić5, I Jukić6. 1. Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia. Electronic address: manuela.miletic@hztm.hr. 2. Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia. Electronic address: tomislav.vuk@hztm.hr. 3. Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia. Electronic address: ana.hecimovic@hztm.hr. 4. Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia. Electronic address: miljana.stojic.vidovic@hztm.hr. 5. Croatian Veterinary Institute, Savska 143, Zagreb, Croatia. Electronic address: jemersic@veinst.hr. 6. Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia. Electronic address: irena.jukic@hztm.hr.
Abstract
BACKGROUND: Seroprevalence of hepatitis E virus (HEV) in blood donors presenting to the Croatian Institute of Transfusion Medicine was assessed with 4 available tests (3 ELISA tests and 1 immunoblot (IB) test). MATERIALS AND METHODS: In October and November 2014, a total of 1,036 serum samples of blood donors were collected for the study. Samples were primarily tested for total HEV antibodies by Dia.Pro HEV Ab test (a). All reactive samples were tested by ELISA tests: Dia.Pro HEV IgG (b) and IgM (c), Mikrogen recomWell HEV IgG_old (d) and IgM_old (e), recomWell HEV IgG_new (f) and IgM_new (g), and IB Mikrogen recomLine HEV IgG (h) and IgM (i). HEV IgM reactive samples also positive by the IB were further tested for HEV RNA. RESULTS: There were 21.5% of samples reactive for total HEV antibodies (a). Seroprevalence of HEV IgG according to the b, d, f and h tests was 20.2%, 9.6%, 18.1% and 17.8%, respectively. Seroprevalence of HEV IgM according to the c, e, g and i tests was 4.4%, 1.5%, 2.0% and 1.7%, respectively. Out of 46 HEV IgM (Dia.Pro HEV IgM) positive samples, 18 (39.1%) were also positive by IB. HEV RNA was not detected in any of those samples. There was a significant association between age and HEV seroprevalence (P<0.001). CONCLUSION: Different HEV antibody detection assays showed a high HEV IgG seroprevalence in Croatian blood donors. Among HEV IgG and HEV IgM positive samples HEV RNA was not detected.
BACKGROUND: Seroprevalence of hepatitis E virus (HEV) in blood donors presenting to the Croatian Institute of Transfusion Medicine was assessed with 4 available tests (3 ELISA tests and 1 immunoblot (IB) test). MATERIALS AND METHODS: In October and November 2014, a total of 1,036 serum samples of blood donors were collected for the study. Samples were primarily tested for total HEV antibodies by Dia.Pro HEV Ab test (a). All reactive samples were tested by ELISA tests: Dia.Pro HEV IgG (b) and IgM (c), Mikrogen recomWell HEV IgG_old (d) and IgM_old (e), recomWell HEV IgG_new (f) and IgM_new (g), and IB Mikrogen recomLine HEV IgG (h) and IgM (i). HEV IgM reactive samples also positive by the IB were further tested for HEV RNA. RESULTS: There were 21.5% of samples reactive for total HEV antibodies (a). Seroprevalence of HEV IgG according to the b, d, f and h tests was 20.2%, 9.6%, 18.1% and 17.8%, respectively. Seroprevalence of HEV IgM according to the c, e, g and i tests was 4.4%, 1.5%, 2.0% and 1.7%, respectively. Out of 46 HEV IgM (Dia.Pro HEV IgM) positive samples, 18 (39.1%) were also positive by IB. HEV RNA was not detected in any of those samples. There was a significant association between age and HEV seroprevalence (P<0.001). CONCLUSION: Different HEV antibody detection assays showed a high HEV IgG seroprevalence in Croatian blood donors. Among HEV IgG and HEV IgM positive samples HEV RNA was not detected.
Authors: Anna Mrzljak; Petra Dinjar-Kujundzic; Mladen Knotek; Boris Kudumija; Mario Ilic; Marijana Gulin; Lada Zibar; Irena Hrstic; Zeljka Jurekovic; Branko Kolaric; Lorena Jemersic; Jelena Prpic; Morana Tomljenovic; Tatjana Vilibic-Cavlek Journal: Int Urol Nephrol Date: 2020-01-01 Impact factor: 2.370
Authors: Tatjana Vilibic-Cavlek; Ljubo Barbic; Anna Mrzljak; Dragan Brnic; Ana Klobucar; Maja Ilic; Natasa Janev-Holcer; Maja Bogdanic; Lorena Jemersic; Vladimir Stevanovic; Irena Tabain; Stjepan Krcmar; Marko Vucelja; Jelena Prpic; Marko Boljfetic; Pavle Jelicic; Josip Madic; Ivana Ferencak; Vladimir Savic Journal: Pathogens Date: 2021-01-15
Authors: Anna Mrzljak; Lorena Jemersic; Vladimir Savic; Ivan Balen; Maja Ilic; Zeljka Jurekovic; Jadranka Pavicic-Saric; Danko Mikulic; Tatjana Vilibic-Cavlek Journal: Pathogens Date: 2021-06-04